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Abstract This article examines how biomedicalisation is encountered, responded to and
negotiated within and in relation to new biomedical forms of HIV prevention. We
draw on exploratory focus group discussions on pre-exposure prophylaxis (PrEP)
and treatment as prevention (TasP) to examine how the processes of
biomedicalisation are affected by and affect the diverse experiences of
communities who have been epidemiologically framed as ‘vulnerable’ to HIV and
towards whom PrEP and TasP will most likely be targeted. We found that
participants were largely critical of the perceived commodiﬁcation of HIV
prevention as seen through PrEP, although this was in tension with the
construction of being medical consumers by potential PrEP candidates. We also
found how deeply entrenched forms of HIV stigma and homophobia can shape
and obfuscate the consumption and management of HIV-related knowledge.
Finally, we found that rather than seeing TasP or PrEP as ‘liberating’ through
reduced levels of infectiousness or risk of transmission, social and legal
requirements of responsibility in relation to HIV risk reinforced unequal forms of
biomedical self-governance. Overall, we found that the stratifying processes of
biomedicalisation will have signiﬁcant implications in how TasP, PrEP and HIV
prevention more generally are negotiated.
Keywords: HIV, sexual health, focus groups, biomedical, gay/lesbian, immigrants/migrants/
refugees
Introduction
Since 2010, a number of major international trials have demonstrated the efﬁcacy of using
antiretrovirals (ARVs) to prevent the transmission of HIV (Cohen et al. 2012, Baeten and
Grant 2013). Unlike research for an HIV vaccine or cure, which seeks to develop new drugs
to prevent acquisition of or eradicate the virus, these trials demonstrated the potential of exist-
ing pharmaceuticals to prevent and manage the sexual transmission of HIV in two new ways.
Treatment as prevention (TasP) is the use of existing treatment to reduce levels of infectious-
ness in people living with HIV. Pre-exposure prophylaxis (PrEP) is the use of ARVs by peo-
ple who are HIV-negative to prevent acquisition of the virus. Together, these two
interventions have garnered signiﬁcant international attention and there have been calls to
make them available to those most at risk of HIV where they are not already available (Jones
2014, The Lancet HIV 2014). Nevertheless, such interventions have also attracted much
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criticism. Kippax and colleagues (Nguyen et al. 2011, Kippax and Stephenson 2012) have
argued that these new interventions are not a panacea for HIV prevention, but need to be part
of a broader approach which integrates social and behavioural dimensions and contexts along-
side these biomedical interventions. Moreover, Kippax has argued that this apparent shift away
from behavioural (i.e. condom-based strategies) to biomedical interventions in the form of
PrEP and TasP is not new but situated in the growing biomedicalisation of HIV prevention
(Kippax and Race 2003, Kippax and Stephenson 2012). These authors trace the shift from
social to biomedical narratives of HIV prevention, attributing the discovery of effective HIV
treatment in 1996 as the pivotal moment in which the biomedical narrative – and approach –
really takes hold. The consequence, Kippax and Stephenson (2012: 796) explain, is that ‘in-
creasing biomedicalisation is distorting prevention efforts’. Instead, they argue for a ‘social
public health’ approach to HIV prevention, which includes biomedical prevention interven-
tions, but which also engages with how HIV is encountered ‘in life – as biological, material,
as informational and technological, as emotional and affective, as social, collective, institu-
tional’(Kippax and Stephenson 2012: 796).
Other have traced the technological shift towards the biomedical much earlier, with the
introduction of the HIV antibody test in the mid-1980s and the emergence of a new biomedi-
cal identity based on sero-status (Flowers 2001, Race 2001). This corresponds with what
Clarke et al. (2003) describe as a wider shift towards biomedicalisation across an expanding
number of health – and increasingly non-health – arenas. From approximately 1985, these
authors chart a signiﬁcant shift from medicalisation to biomedicalisation. That is, there has
been a move from ‘medicine exerting clinical and social control over particular conditions to
an increasingly techno-scientiﬁcally constituted biomedicine also capable of effecting the
transformation of bodies and lives’ (Clarke et al. 2003: 165). However, rather than viewing
biomedicalisation as deterministic, they see human action and technoscience as ‘co-constitu-
tive’. Their project in charting biomedicalisation is to identify and create new critical spaces to
enable ‘greater democratic participation in shaping human futures with technosciences’ (Clarke
et al. 2003: 166). This article responds to Clarke et al.’s project and examines how biomedi-
calisation is encountered, responded to and negotiated within and in relation to new biomedical
forms of HIV prevention. We draw on exploratory focus group discussions on PrEP and TasP
with participants from diverse communities affected by and/or at risk of HIV in the UK. We
consider how the processes of biomedicalisation are affected by and affect the diverse experi-
ences of communities who have been epidemiologically framed as ‘vulnerable’ to HIV and
towards whom PrEP and TasP will most likely be targeted in public health policy. In particu-
lar, we consider how PrEP and TasP are imagined, produced and negotiated through the
diverse social, material and technological environments in which study participants inhabit,
and within a broader framework of the biomedicalisation of HIV prevention.
Biomedicalisation
Where Kippax and Stephenson note the impact of biomedicalisation on the speciﬁc direction
of HIV prevention research, policy and practice, the broader biomedicalisation thesis offers an
overarching conceptual framework within which to understand many developments in contem-
porary health-care (Clarke et al. 2010). Biomedicalisation addresses the complex networks and
agents that constitute, and are constituted by novel, and often highly technologically mediated,
processes of medicalisation. The broad and inclusive framework captures the ﬂuid, technologi-
cal and expanding repertoire of processes, structures and disciplines now appropriated into the
exercise of what could be called biopower (Foucault 1984), and what has been described as
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the production of the biosocial (Rabinow 1996). Together these approaches stress the recipro-
cal interplay of the psychosocial, sociocultural, politico-economic and biomedical domains.
Clarke et al. (2010) detail ﬁve central tenets of this historical shift from medicalisation to
biomedicalisation. First, major politico-economic shifts enable expansion of the privatisation
and commodiﬁcation of medicine and medical research, with the resultant centralisation,
rationalisation and devolution of health services. Second, there is a distinct focus upon health
rather than illness per se, with a concomitant increase in new forms of risk and surveillance.
Health is cast as a moral obligation as the body becomes a legitimate site for increased inter-
vention, enabled and constituted through biomedical forms of self-governance, enacted through
health and biological citizenship (Petersen and Lupton 1996, Petryna 2002, Rose 2007). Third,
the technological and scientiﬁc ways in which we understand health are expanding, based on:
an increasing computerisation and centralised storage and organisation of medical data; a
molecularisation and geneticisation of health (Rose 2007); and the transformation of medical
developments through digitisation and hybridisation to create new biomedical technologies.
Fourth, there is a transformation of information and the production and distribution of knowl-
edge. This includes: an increase and diversiﬁcation of health-related information which chal-
lenges the lay-expert knowledge divide; a co-option of competing knowledge systems; and
new techniques to legitimate biomedical claims (e.g. randomised control trials). Fifth, biomedi-
calisation results in the transformation of bodies and identities, ascribing new technoscientiﬁc
and biosocial identities on both an individual and collective level (Rabinow 1996).
Biomedicalisation suggests that technoscience and biomedicine leach into, and construct,
everyday life with a proliferation of risk and uncertainty. Biomedical research and its therapeu-
tic applications, such as assisted reproductive technologies, genetic testing for cancer, and
blood, organ and tissue transplantation, can be understood as playing an increasingly important
role in the everyday experiences of health and illness (Petryna 2002, Waldby and Mitchell
2006, Lock and Nguyen 2010). However, the processes of biomedicalisation are both tempo-
rally uneven and stratiﬁed, with the potential to augment existing – and create new – forms of
difference and health inequalities. And yet, biomedicalisation is not a ‘technoscientiﬁc tsunami
that will obliterate prior practices and cultures’ (Clarke et al. 2003: 185) , but one which cre-
ates new sites of negotiation, knowledge, agency and citizenship. The heterogeneity of
biomedicalisation and the co-constitutive impact of different lived experiences necessitate
focused examination of particular biomedicalisation processes, situated in their speciﬁc – but
globalised – contexts. Developments in the preventative potential of HIV treatments through
PrEP and TasP, legitimated by international clinical trials and expanding the technoscientiﬁc
nature of HIV prevention practices, provide a productive arena in which to examine the emer-
gence of biomedicalisation in a contemporary context.
TasP and PrEP
In 2011, the clinical trial HPTN052 was stopped early when it determined that, when people liv-
ing with HIV took ARVs earlier than the standard of care clinical indications, the risk of HIV
transmission to sexual partners was signiﬁcantly reduced. Conﬁrming what had earlier been
claimed in the Swiss Statement (Vernazza et al. 2008) but which was widely rejected due to lack
of clinical trial evidence, HPTN052 trial ﬁndings demonstrated that ARVs used to manage HIV
and lower HIV viral loads to ‘undetectable’ resulted in signiﬁcantly reduced levels of infectious-
ness and reduced risk of transmission by 96 per cent (Cohen et al. 2012). Many public health
researchers and policymakers responded to TasP by modelling, testing and measuring the wider
public health beneﬁts of early HIV treatment initiation across communities (HIV Modelling
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Consortium Treatment as Prevention Editorial Writing Group 2012). There is currently mixed
clinical evidence as to the added health beneﬁts of early treatment for individuals living with
HIV, in spite of the global policy context which increasingly favours a TasP-based approach to
HIV prevention (WHO 2013). Moreover, these clinical ﬁndings have been translated into public
health policy in diverse ways. For instance, the British HIV Association (BHIVA) has accepted
the clinical evidence of TasP, but advises that starting treatment ‘early’ to prevent transmission to
a sexual partner be explored on an individual patient basis. These guidelines add that any treat-
ment decision must not be through undue pressure from a sexual partner and/or clinician (BHIVA
and EAGA 2013). In contrast, the province of British Columbia (Canada) has implemented TasP
policy which means that anyone diagnosed with HIV is to start treatment immediately (British
Columbia Ministry of Health 2012). As increasingly more countries are exploring and/or imple-
menting new treatment guidelines (Morlat et al. 2013), TasP is quickly becoming standard prac-
tice in HIV treatment and prevention decisions.
There have been many international, multi-site clinical research trials funded and initiated to
determine if PrEP was safe and effective as an HIV prevention method. These trials found
daily and consistent use of ARVs would reduce the risk of HIV transmission, ranging between
44 per cent in the iPrEX trial in 2010, up to 86 per cent most recently in the PROUD trial
with gay and bisexual men in the UK (Baeten and Grant 2013, McCormack 2015). Many have
described drug adherence as critical to the clinical ﬁndings (Bangsberg 2014), with poor
results of some studies attributed to lack of participant engagement with the trial itself, result-
ing in participants not taking the medication (van der Straten et al. 2014). In 2012, the US
Food and Drug administration approved Truvada for use as PrEP (Food and Drug Administra-
tion (FDA) 2012), although the decision was not without controversy. Unlike TasP, public
health policymakers and practitioners in many countries have so far been wary of ofﬁcially
sanctioning PrEP as an HIV prevention option on the grounds of mixed clinical evidence
(McCormack et al. 2012), not to mention the potential for ‘mis-use’. However, there is consid-
erable activism and discussion aimed at widening access to PrEP beyond the US context, espe-
cially given recent clinical trials results in the UK (Jones 2014, The Lancet HIV 2014).
The potential of pharmaceutically-based HIV prevention options has resulted in an uneven
ﬂurry of ‘acceptability’ research, which explores if and how potential PrEP or TasP ‘candi-
dates’ might use these interventions. Much of this research has been framed largely through a
fear of the potential abandonment of condoms (resulting in potentially increased risk of HIV
transmission) and or that individuals will fail to take their medication regularly or consistently
(Young and McDaid 2014). This narrow conceptualisation of ‘acceptability’ excludes a range
of factors and contexts which might affect potential uptake and use of these interventions.
Nevertheless some researchers have endeavoured to understand the wider social context in
which PrEP or TasP might be used (Guest et al. 2010, Ware et al. 2012), or indeed, have
sought to situate these relatively new interventions in a broader theoretical context (Rosen-
garten 2010, Persson 2013, Holt 2014). Most pertinent to our research, Persson (2013) high-
lights the need to better understand the potential dissonances between the biomedical rhetoric
around emerging new biotechnological interventions and the lived experiences of those who
might use, shape and be shaped by these technologies. In the remainder of this article, we will
explore these potential dissonances through qualitative research conducted in Scotland.
The study
Gay, bisexual and/or men who have sex with men1, and men and women from migrant Afri-
can communities2 are disproportionately affected by HIV and currently represent over half of
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all new HIV diagnoses in Scotland (Health Protection Scotland 2013). Although these two
communities are distinct from each other in terms of epidemiological, social and economic
experiences of HIV (while also recognising the heterogeneity within these broad groupings),
they represent the groups towards which PrEP and/or TasP will most likely be initially tar-
geted in public health policy. HIV and the Biomedical is a qualitative study which explored
how PrEP and/or TasP might be responded to and/or incorporated into the everyday lives of
gay men, and African men and women living in Scotland. Drawing on well-established quali-
tative methods (Barbour and Kitzinger 1999, Silverman 2000), we conducted exploratory focus
groups (FGs) to explore and situate PrEP and TasP in a wider social context, paying particular
attention to language, social dynamics and resonances/dissonances with sexual practice and
other health technologies. This research informed subsequent in-depth interviews, reported on
elsewhere (Young et al. 2014). This article reports on the FGs themselves.
Participants were recruited through existing community and/or support groups in order to
build on established group rapport and dynamics, enabling discussions of sensitive topics.
Groups were identiﬁed with the assistance of community research partner sexual health and/or
LGBT organisations based in Scotland who support regular groups to discuss HIV, sexual
health and other support needs. We held the FGs in four cities reﬂecting a range of urban and
semi-rural Scottish locations, including its two largest cities. We conducted FGs with 33 par-
ticipants who were either gay men or African men and women between August and November
2012. FGs were organised by sero-status and ethnic and/or sexual identity. We ran ﬁve FGs
with twenty-two gay men, including three with HIV-positive men, and two with HIV-negative
or untested men. We ran two FGs with 11 African men and women (eight women, three
men), including one HIV-positive group. Participants ranged in age from 18 to 75 years across
all groups.
FG discussions were facilitated by IY and/or PF. Participants were ﬁrst asked about their
understandings and management of sexual health risks, paying particular attention to the role
of sexual health technologies within these strategies. Participants were presented with a range
of items, such as condoms (male and female), sachets of lubricant, a home pregnancy test,
an emptied bottle of Truvada, a mock-up bottle of antibiotics, a chart of available ARVs,
images of Oraquick In-Home HIV test and a rapid ﬁngerprick HIV test. PrEP and TasP
were then explained to participants with the help of visual aids (Young et al. 2014). Speciﬁc
rates of effectiveness were not provided, but the facilitator explained the varying rates of
efﬁcacy identiﬁed in a number of clinical trials. Participants were then asked to discuss PrEP
and TasP in relation to their own sexual health, including if and how they might be used.
The study received ethical approval from the University of Glasgow College of Social
Sciences Ethics Committee. Participants provided written consent before the discussion
started and received £15 voucher and travel costs. FGs were digitally recorded, transcribed
verbatim and names and any identifying features were removed from the transcriptions. Data
were analysed thematically; IY and PF independently analysed half of the transcripts by
identifying emerging themes and issues and made notes in an analysis booklet through the
process of reading and rereading until saturation. Notes were guided by four analytic cate-
gories: descriptive/content; interactional dynamics; microanalysis/key discourse; and general
theme. The analysed transcripts were then exchanged and re-analysed, building on the origi-
nal researcher’s notes. Once each transcript had been seen and analysed twice, key themes
were discussed and agreed. Rigour throughout the analysis was achieved through an iterative
process of discussion and revision of ﬁndings (Barbour and Kitzinger 1999, Mason 1996,
Silverman 2000). Here, we present three of the main themes to emerge from this analysis,
which illustrate how the processes of biomedicalisation are negotiated and contested in rela-
tion to PrEP and TasP.
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Contesting the commodiﬁcation of HIV prevention
Commodiﬁcation and privatisation of medicine, the ﬁrst tenant of biomedicalisation, shaped
the responses of many participants. For instance, questioning the role that private, for-proﬁt
pharmaceutical companies might have played in developing and marketing PrEP was a com-
mon response amongst HIV-positive participants, and especially amongst HIV-positive gay
men. These critiques often shaped the questioning or even immediate rejection of PrEP as an
acceptable prevention option. The perceived association between PrEP and ‘Big Pharma’ for
many rendered these new pharmaceutically-based interventions immediately suspect; partici-
pants suggested that the motivation for proﬁts led them to question the scientiﬁc credibility
and effectiveness of PrEP to actually work:
Respondent 1: How much does the tablet cost?
R2: It’s a money making exercise for the Americans. That’s all it is.
R3: It’s like a multi-vitamin. It doesnae [doesn’t] work.
R4: Or is it a case of . . .
R2: No Americans, drug companies.
R3: Aye, totally, as well.
R2: It’s the drug company’s way of making money. (HIV-positive gay men)
The critique of PrEP as driven by proﬁt was augmented by the claim that it was driven by
American drug companies. Rather than seeing drug companies as part of multi-national con-
glomerates, a characteristic of many contemporary depictions of pharmaceutical and globaliza-
tion (Petryna 2009), their scepticism was grounded in a perception of the dominance of
American companies in global medical markets. In contrast to a privatised, American health
system epitomised by these companies, a free public health system funded through collective
taxation appeared to be highly valued by HIV-positive participants, most of whom accessed
their own HIV treatment without direct cost to themselves. While the initial question in the
above extract about cost of PrEP was overtaken by a collective rejection of American drug
companies, it was an issue which emerged across many of the discussions in relation to PrEP
provision within a publically funded health system. Conscious of the cost of their own medica-
tion, participants questioned the wisdom of creating more demand for expensive drugs in an
already over-stretched system:
I mean it costs a blooming fortune just to feed the existing people who are infected with
these drugs. So to actually encourage the whole population to conduct themselves in such a
way that they not only used protected facilities like condoms but then they take a wee
[small] pill and we all remember what it was like when you started taking pills, they make
you sick. So if the pill makes you sick, when you’re healthy, it then, then you’re gonna stop
taking the pill. (HIV-positive gay man)
Participants drew on their own experiences of starting treatment and enduring difﬁcult and
long-lasting side effects to understand how PrEP might work for others and were concerned
about the potential for ﬁnancial waste if people stopped taking the drugs. By casting PrEP as
optional and HIV-negative PrEP users as healthy, HIV-positive participants not only invoked a
clear division between essential and non-essential use of ARVs, but also the necessity of
continued adherence. Given the potential risk of non-adherence, availability of condoms and
a ﬁnite set of resources, many HIV-positive gay men deemed PrEP as inappropriate for a
publicly funded health system. This not only speaks to the rationalisation of health services
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(Clarke et al. 2003: 170), but also to the economisation of health services which demands
cost-containment and compliant users (Ewert 2009).
HIV-positive African participants also expressed concerns about the use of ARVs for pre-
vention situated within the context of resource-limited health systems. However, in contrast
to the descriptions above, these participants drew on their experiences of HIV treatment and
care outside of the UK to frame their understandings of PrEP and TasP. African participants
came from a diverse range of countries, reﬂecting a mix of health system failures and suc-
cesses in providing HIV treatment and care. In addition, FG participants reﬂected a wide
range of experiences within the UK, ranging from recent arrivals to long-term UK resi-
dency. Yet, within these diverse contexts, many of the HIV-positive African participants
described either family members’ or their own difﬁculties in accessing treatment, or having
to rely on earlier generations of ARVs resulting in increased drug toxicity and tablet num-
bers. When one participant described taking nine tablets a day, others thought it was ‘too
much’ in comparison to currently the standard of care in the UK (HIV-positive African
group). Grounded in this perceived unequal access to and burden of treatment, some partici-
pants critiqued the use of ARVs where they were not intended for people diagnosed with
HIV, and even to criticise the wider language of HIV prevention and cure claims. One man
explained:
We want to send a message to the scientists. Look when you talk about the guy who was
cured in Germany seems they’ll be looking at the rich not to the poor. Because that’s not
fair. Why they have to write something or call this a cure if they know there’s billions of
people cannot afford it? (HIV-positive African man)
For this participant, the response to PrEP and TasP was embedded in the knowledge and expe-
rience of the global politics of biomedical research and discovery; participants were engaged
in these politics in as much as they were aware of and directly affected by inequalities in
access not only to new therapies, but to essential HIV treatments. This reaction highlights the
way in which experiences of migration and global health inequities shape responses to PrEP
and TasP within the context of the global markets of biomedical HIV prevention and care.
However, the critique of PrEP as an inappropriately commodiﬁed HIV prevention option
was not shared amongst all participants. In particular, HIV-negative and untested gay men
expressed none of the same concerns about the role of American drug companies in the intro-
duction of PrEP. While not unanimously embracing PrEP as a prevention option, these partici-
pants were concerned about more local (UK) inequalities of access:
R1: Like if they know it works why can they not bring it tae [to] Britain? If it’s
already been proved in America to be sold in America? Why not bring it to
Britain? . . . ‘cause we’re that bloomin’ much up each other’s bums anyways . . .
R2: Is it not because . . . there’s different laws in Europe than there is from America
about what medication you’re allowed tae [to] take an’ stuff . . . Like there’s
some in America that they’re not allowed to have but we’re allowed to have it
over here, an’ there’s ones that we can have over – like ones that we can’t have
over here that they’re allowed over there . . . There’s like rules an’ stuff of
certain – like a certain –
R3: Totally, laws are different.
R1: See the folk in Parliament if they look at the statistics, if they reckon HIV’s
goin’ up an’ all that stuff, then – an’ if it’s been proved in America – then they
should just get off their high-horses an’ change the law themselves.
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R3: They’ll have to sell it to us ﬁrst ‘cause they’ve got it an’ they’ve produced it.
They’ll have to sell it to us won’t they? If we wanted it in the UK, they’d have
to sell it to us. (HIV-negative gay men)
In contrast to the criticisms by HIV-positive participants, these men viewed the complexities
of international drug markets as potentially obstructing access to PrEP. Indeed, seeing the gov-
ernment and international trade laws as the barrier to open markets for HIV prevention com-
modities signals the men’s constructions of the medical consumer who should have access to
these products should they choose. They explain that this is especially critical given the rising
rates of HIV and the availability of an apparently effective prevention option. For these partici-
pants, it is the pharmaceutical market and not the national health system which enables access
to critical HIV prevention solutions.
Although participants’ responses to PrEP are grounded in very different interpretations of
the commodiﬁcation of HIV prevention, they are all equally grounded in notions of equity in
access. While those participants who are reliant on publically-funded health systems for their
care are concerned about non-essential use of resources in shrinking health systems and poten-
tially increasing inequalities in global markets, participants with limited engagement with
health services to date view access and choice as critical factors in maintaining good health.
What is important to note here is how the commodiﬁcation of HIV prevention technologies
and the notion of health equity shape the response to and acceptability of PrEP and whether
(or not) it should be made available through existing, publically-funded health infrastructures.
Contesting stigma and access to knowledge
Clarke et al. (2003: 177) argue that the production and transmission of knowledge are key
sites of biomedicalisation in relation to who is ‘responsible for grasping and applying such
knowledges’. We found that participants were highly attuned to existing forms of HIV stigma,
and its implications for access to PrEP, TasP or general biomedical HIV-related information.
Integral to discussions about TasP were anxieties about who would have access to this infor-
mation because of the role it might play in reducing HIV-related stigma. HIV-positive gay
men were concerned that this information was not available or understandable through exist-
ing, gay-scene based messages for those not affected by HIV:
But if you’re on tablets, it reduces the infectiousness of HIV if you’ve got an undetectable
viral load so you’re less risk to your partner, passing it on, and I think it’s only people that
know about HIV that really know about that, or people who’ve actually read into it or
who’ve got friends who know about it as well. So it’s all about word of mouth. That kind
of thing’s not advertised on the scene. There’s so many sexual health messages out there as
well. (HIV-positive gay man)
Participants were concerned that the existing sero-divide (division on basis of HIV-status)
would negatively affect how TasP was understood: it was not the type of message available,
nor would it ﬁlter through the myriad of sexual health messages currently in circulation. In the
above extract, participants cite the importance of proximity to HIV (Keogh 2008) in accessing
this information. Implicit in these observations is the notion that not living with HIV – or
being close to those affected by HIV – shapes what information is accessible and who has
access. Participants were concerned that existing forms of HIV-stigma would preclude those
not affected by HIV from engaging in this critical ‘new’ information about HIV risk.
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Discussions highlighted how risk of HIV-related stigma is often framed as ‘lacking knowl-
edge’ and, as such, represents a complex challenge to the acceptability of PrEP/TasP. The fol-
lowing exchange with HIV-negative African participants addresses the potential reaction to
PrEP by others, and how this might be managed within the context of HIV-related stigma that
risks conferring an HIV-positive identity to the potential PrEP user:
R1: The normal, normal to day-to-day person they think that, I mean it’s that thing
when people use medication to conﬁrm somebody’s illness it’s almost like, ‘oh I
saw that bottle, I saw that medicine’, or ‘they are on antibiotics that means that
they are on that, that they’ve got that infection’ . . . It’s almost like medication is
. . . conﬁrms people’s suspicions.
R2: Yeah, but I think for this one it might be different because people would know
what it does, you know they will know that some people can take it although
they don’t have the disease.
R1: How many, how many know that? You know? . . . We’ve got a true advantage,
we know. Like me, before I can carry this out, I will know that everybody they
are aware of it, like maybe through campaign or advertisement that this thing
can cure it can help you the risk. Then, I can be able to take it along with me
and when they ask me I will give it to them to read.
R3: If you had one partner, what would it mean for your partner? But would you not
be, in a way, exposing your partner then if you are going around saying, ‘no I’m
taking this medication’.
R1: No, no, no, you don’t understand. It’s not that. I’d be taking it like, like it might
be in my, in my bag. You know maybe someone want to take something my
bag, go an check it in my bag and saw it there.
R2: Yes. Well then you would explain to them –
R1: No. Only if, only if, that person asked, then I would give it to her to read, or to
that person to read. Is for prevention. If it say it work? I say I dunno it’s for
prevention, to prevent myself. (HIV-Negative/untested African Participants)
In this extract, participants describe a shared understanding of HIV-related stigma amongst
their families and friends. One participant in particular describes a set of strategies to manage
this stigma, which rely on distancing herself from HIV and limiting the possibilities of expo-
sure to this stigma. Critical to this management is her own knowledge of PrEP and ability to
communicate this, indicating the way in which PrEP users might be assumed to also need to
be PrEP advocates. Moreover, she assumes that PrEP would be accompanied by an institution-
ally sanctioned education campaign, thus corroborating her story and decreasing the chances
of her being ‘mistaken’ as HIV-Positive. The expectation that biomedical knowledge about
PrEP will be deployed in a very particular way points to the how shared perceptions of stigma
interact with assumptions about who has access to PrEP knowledge.
Not only did HIV-stigma play a signiﬁcant role in the acceptability of PrEP and TasP, but it
was an important factor in how HIV-negative participants managed their own HIV-negative
identities and inﬂuenced discussions around HIV-prevention more generally. One group of
young, HIV-negative/untested gay men articulated a general mistrust of PrEP and TasP as reli-
able prevention methods. They described preferring to rely on condoms, or more commonly,
selecting sexual partners on the basis of their (often assumed) HIV-negative status. Underlying
these strategies were concerns about homophobia and the role it could play in blurring distinc-
tions between being at high risk of HIV and being HIV-positive:
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R1: Wi’ cancer . . . a lot o’ people . . . well they know deﬁnitely they can’t catch
cancer, but you’ve got so many old fashioned folk still in this world that if you
. . . If your laundry was aired publicly that you had HIV, you’d lose friends like
that [clicks ﬁngers]. You’d walk along the high street an’ people would move
out the way, d’you know what I mean? Because a lot of people are just so . . .
non-educated about the different types of like infection an’ diseases you can get,
d’you know what I mean? I mean I can imagine me, if I had HIV an’ everybody
knew like all these little school kids just like, “oh he’s got AIDS, get away from
him,” d’you know what I mean?
R2: ‘Cause you already get that even though you dinnae [don’t] have it, you still get
that folk that’s homophobic sayin, “oh you’ve got AIDs, an’ you’ve got that”
R3: Because you’re gay, like it’s the stigma.
R2: . . .because you’re gay. (HIV-negative/untested gay men)
These complexities of negotiating gay identities in a perceived homophobic society highlight
how participants sought to resist the elision of being gay with being HIV-positive. For these
young men, limiting proximity to HIV could be seen as strategy to manage homophobia in the
context of a society that was not ‘educated’ about HIV. Indeed, the men in this group repeat-
edly talked about maintaining conﬁdentiality around their sexual health because they lived in a
small community:
I couldn’t go to [the local] GUM clinic ‘cause if I saw someone sittin’ ootside that I ken
[knew], it would look like that I had everything, d’you know what I mean? Whereas my
doctor they [don’t know] what I’m goin’ in for an’ I ﬁnd it a lot safer . . . So I go to my
doctors I ﬁnd it more secretive an’ conﬁdential. (HIV-negative/untested gay man)
While concerns about being seen at the local sexual health clinic are not limited to small com-
munities, these anxieties highlight the work these men do in managing public perceptions of
both their sexual identity and sexual health. This work has implications for HIV prevention;
the intersections of different forms of stigma (i.e. homophobia, HIV-stigma) and other social
‘risks’ (i.e. ignorance about HIV) could be managed in ways that distance or limit any engage-
ment with HIV.
The responsibility and culpability of HIV prevention
The biomedicalisation thesis posits that health has become a moral obligation. This confers
upon the individual a responsibility to be and remain healthy, enforced through disciplinary
forms of self-governance (171–2). Similarly, discussions around the use of PrEP or TasP were
framed by this sense of responsibility for HIV prevention and requirement of self-governance.
However, these discussions were also strongly shaped by the notion that certain groups of peo-
ple – speciﬁcally people diagnosed with HIV – were more responsible than others for prevent-
ing transmission. This prevention imperative can be seen in how many HIV-positive
participants described managing their own health practices to reduce the risk of transmission
to others. For instance, many HIV-positive African women described how their testing prac-
tices related directly to preventing mother-to-child transmission. One woman, who learned her
HIV status during her pre-natal care, explained planning to test for HIV only when she
became pregnant because of the transmission implications for the foetus, and not her own
health. Before she was pregnant, she told herself: ‘you know what, no matter what, when I’m
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pregnant I’m going to test myself’ (HIV-positive African woman). In relation to PrEP, the
implications of this prevention imperative can be seen in anxieties expressed about trust and
control by HIV-positive participants. One woman explained her scepticism of PrEP as an
effective prevention method because it was not her, but her sexual partner in control of it:
‘[PrEP] is too risky for him because I don’t know when he stop using it, what will happen to
him’ (HIV-positive African woman). Instead of viewing her partner’s potential non-adherence
to and subsequent diminished protection from PrEP as his responsibility, she took on the
responsibility for both parties and dismissed PrEP as a potential option for her serodiscordant
partnership.
This prevention imperative, and requisite forms of self-governance, underpinned responses
to PrEP and TasP. Although somewhat contested by HIV-positive participants, there was a
clear sense of the heightened social responsibility and culpability for managing the risks of
HIV transmission. The following extract from a discussion with HIV-positive gay men high-
lights how perceptions of responsibility for HIV prevention might affect potential uptake of
PrEP or reliance on TasP:
R1: People with HIV have more responsibility.
R2: No.
R3: Yeah, I think . . .
R2: People are responsible for their own sexual health so I think both actually. Not
necessarily someone using PREP because maybe the HIV-negative person might,
what the word I was looking for? . . . might resent starting PrEP ‘cause they’re
thinking ‘I’m starting this, taking these pills, they’re making me feel rotten, why
do I need to do this? Why can’t I just use a condom?’ So maybe it’s a bit of
both.
(. . ..)
R1: Generally I hear again and again, and it’s sometimes directly or sometimes
indirectly, men who are negative or presumed to be negative saying that if
you’re HIV-positive you’ve got to protect everybody. It’s your responsibility.
I’m negative so it’s nothing to do with me. So people who are HIV-positive
have all the responsibility to protect negative men. So in that scenario I wonder
what they’d say ‘well obviously you start treatment, you’re the one who’s got
the disease, I don’t have it’.
R2: No I think it’s up to . . .
R3: Everybody’s responsible for their own . . .
R1: . . . not everybody like Peter, not everybody is encouraged to go on drugs
straight away. So the negative person wouldnae [wouldn’t] necessarily get the
idea that although Peter is positive, he isnae [isn’t] at risk yet.
R2: I think we’re all responsible for our own actions. (HIV-Positive gay men)
Although there was some debate about whether responsibility for the prevention of HIV trans-
mission was shared, or if HIV-positive individuals were more responsible than others, this dis-
cussion also highlights the TasP-speciﬁc anxieties of HIV-positive participants in this regard:
they may be held to account for either risk of HIV transmission, or the effects of taking medi-
cation to prevent HIV transmission. In other words, the stigma-driven sero-divide in responsi-
bility exacerbates the culpability of HIV-positive individuals when demanding additional
behaviour/precautions by HIV-negative sexual partners. This additional biomedical responsibil-
ity overlaps with a further element of biomedicalisation: the transformation of bodies to
include new properties. In this case, we can see the increased responsibility of diagnosed HIV-
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positive individuals to prevent transmission upon the acquisition of their new biomedical iden-
tity (Race 2001). However, participants felt that TasP complicated the social reception of this
biomedical identity, in that not all diagnosed HIV-positive people, like Peter, were on treat-
ment. This raised concerns amongst participants that TasP could lead to a misinterpretation of
the protection of ARVs as universal, further complicating their own role in preventing poten-
tial transmission.
While HIV-positive participants were reassured by TasP in managing potential transmis-
sions, there was a sense that this was in no way sufﬁcient to offset the range of risks and
responsibilities they incurred from being HIV-positive. Moreover, the responsibility to manage
HIV by this group was made apparent through the law:
R1: I think it’s a good idea coz if you’re less likely to pass it on, and that’s a proven
fact, I think that’s a good idea – coz you’re then preventing, you’re reducing the
risk to other people so you’re then reducing other people who are on medication.
Q: Mm, but you’re increasing you’re, the amount of time you’re on medication.
R1: Does that really make any difference? Because if you’re HIV-positive and don’t
know the status of the person you’re sleeping with, that you’re more inclined to
use condoms or position yourself differently so the risk is reduced to them. But
it’s also so the criminalisation of risk and the transmission risk as well, so is this
really worth it? Because you can still get prosecuted for it, putting somebody at
risk, even if it’s just a nominal risk. . .. (HIV-positive gay men)
Concerns about the potential prosecution of HIV transmission shaped the responses of some
HIV-positive participants to the possibility of using TasP; the role of the state and legal system
in these concerns highlights how the institutional processes of biomedicalisation are present in
the most intimate of contexts (Weait 2007).
Conclusion
This article has explored the ways in which the acceptability and potential use of PrEP and
TasP are affected by – and affect – processes of biomedicalisation. Yet, as we have seen, the
biomedical does not function independently: the social, cultural and material shape the pro-
cesses of biomedicalisation in varied and uneven ways. We found that responses to PrEP
evoked the commodiﬁcation of HIV prevention through the critiques of ‘Big Pharma’ and
HIV science, as well as through implicit demands for more equitable health systems. Yet, not
all were sceptical of the open market system in its ability to facilitate improved health options,
including potential PrEP consumers. We also identiﬁed how deeply entrenched forms of HIV-
stigma and homophobia can shape and obfuscate the consumption of PrEP and TasP knowl-
edge. At the same time, participants drew on certain forms of knowledge as liberating and as a
way of overcoming stigma in the social management of PrEP. Finally, we found that responses
to TasP and PrEP were shaped by the construction of HIV-positive bodies as risky, and the
accompanying responsibility of those with HIV-diagnoses to manage this risk. Thus, rather
than seeing TasP or PrEP as ‘liberating’, for instance through reduced levels of infectiousness
or risk of transmission, social and legal requirements of responsibility in relation to HIV risk
reinforced unequal forms of biomedical self-governance.
Our ﬁndings echo and build on Persson’s (2013) work, who found that biomedical messages
about HIV infectiousness were met with ambivalence, grounded in contingent and changing
experiences of HIV corporeality. Similarly, we found that the division between people diag-
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nosed with HIV and those who are (or are assumed to be) HIV-negative fundamentally shaped
responses to TasP and PrEP, in spite of the potential of these prevention options to break
down these very barriers. This has signiﬁcant implications for not only the acceptability of
these interventions, but also how PrEP and TasP are implicated in maintaining or exacerbating
this biomedical stratiﬁcation. Others have detailed the stratiﬁcation of biomedicalisation in
heart disease and how the disjuncture between expert and lay understandings were framed
through race, gender and poverty (Clarke et al. 2010). Our work highlights how responses to
TasP and PrEP are grounded not solely in an expert/lay divide or economic inequalities per se,
but in a sero-divide that is perpetuated through the ‘emergent dividing practices’ (Clarke et al.
2003: 184) of the very biomedical processes themselves. Yet, the uneven patterning of
biomedicalisation is ampliﬁed and further manifested in the nexus of traditional lines of
inequalities such as sexual identity, ethnicity, migration/mobility, gender and geography. Cri-
tiques of these biomedical prevention interventions are therefore right to be grounded in the
language of biomedicalisation. Our work details how, in addition to overarching biomedi-
calised policy shifts (Kippax and Stephenson 2012), the subtle biomedicalised transformations
at the micro level have signiﬁcant implications for TasP and PrEP negotiations.
Our work was exploratory and suggestive of the heterogeneous effect of biomedicalisation
on particular HIV interventions. However, our ﬁndings suggest a potentially growing gulf
between HIV-positive and HIV-negative communities in terms of health expectations and
experiences of negotiating biomedical prevention. It also raises a number of questions about
what equitable and fair HIV prevention looks like, how this might manifest across diverse
communities and who is or will be implicated in the increasingly biomedical moral imperative
to prevent HIV. As Holt (2014) suggests, this has not been, nor will be a straightforward pro-
cess. Yet as prevention technologies like TasP and PrEP increasingly become more regular
facets of biomedicalised HIV practices, we need to attend to the material, lived and stratiﬁed
experiences of diverse communities affected by HIV.
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Notes
1 For the sake of brevity, we will refer to this group as gay men.
2 We refer here to diverse communities as this group includes men and women from multiple, sub-Sa-
haran African countries where HIV is endemic. Again, for brevity, we will refer to this group as Afri-
can men and women.
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